Posted by Michael Wonder on 21 Apr 2022
AbbVie’s Crohn’s disease drug given green light by MHRA
21 April 2022 - An estimated 217,000 people aged 16 and over live with the condition in the UK.
The UK MHRA has issued a positive opinion under the Early Access to Medicines Scheme for AbbVie’s risankizumab.
